Leading the World in Tumor Re-Engineering
PsiOxus aims to be the world’s leading company in tumor re-engineering, delivering medicines of value to patients with cancer.
PsiOxus is a clinical stage oncology company pioneering systemic immune oncology products that drive sustained reprogramming of the tumor microenvironment to overcome the central challenge of resistance to therapy.
Our validated T-SIGn® vector platform can deliver multiple transgene payloads that re-engineer both primary and metastatic tumors. We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer.